睿知中国疾病研究地图
候选清单0

即将招募鼻咽癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
  2. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07818486,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;

    入选标准第 9 条

    Active infection requiring systemic therapy within 4 weeks prior to the first dose of study drug;

    排除标准第 16 条

    Pleural, peritoneal, or pericardial effusion requiring drainage and/or associated with symptoms within 4 weeks prior to the first dose of study drug;

    排除标准第 17 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no deterioration within 2 weeks prior to the first dose;

    入选标准第 8 条

  4. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (aPTT) ≤1.5 × upper limit of normal (ULN);

    入选标准第 12 条

  5. Must have at least one measurable lesion as defined by RECIST v1.1;

    入选标准第 7 条

  6. Use of chemotherapy, biotherapy, immunotherapy, or other systemic anti-cancer therapies within 4 weeks or 5 half-lives prior to the first dose;

    排除标准第 1 条

    Diagnosis of another primary malignancy within 5 years prior to the first dose;

    排除标准第 5 条

    Positive for human immunodeficiency virus (HIV) antibodies, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;

    排除标准第 15 条

  7. Pregnant or breastfeeding women;

    排除标准第 20 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07818486,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily sign the informed consent form and agree to comply with the protocol requirements;
  2. No gender restriction;
  3. Age: ≥18 years and ≤75 years;
  4. Expected survival time ≥3 months;
  5. Recurrent or metastatic nasopharyngeal carcinoma and other solid tumors;
  6. Agree to provide archived tumor tissue specimens or fresh tissue samples from the primary or metastatic lesions within 3 years;
  7. Must have at least one measurable lesion as defined by RECIST v1.1;
  8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no deterioration within 2 weeks prior to the first dose;
  9. Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
  10. No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%;
  11. Organ function levels must meet the required criteria;
  12. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (aPTT) ≤1.5 × upper limit of normal (ULN);
  13. Urine protein ≤1+ or ≤1000 mg/24h;
  14. For premenopausal women of childbearing potential, a serum pregnancy test must be performed within 7 days prior to the start of treatment and must be negative, and they must be non-lactating; all enrolled patients (both male and female) must adopt adequate barrier contraceptive measures throughout the entire treatment period and for 6 months after the completion of treatment;
  15. The trial participant must be capable of and willing to comply with the visit schedule, treatment plan, laboratory tests, and other study-related procedures specified in the protocol.

排除标准:Exclusion Criteria:

  1. Use of chemotherapy, biotherapy, immunotherapy, or other systemic anti-cancer therapies within 4 weeks or 5 half-lives prior to the first dose;
  2. History of severe cardiac or cerebrovascular disease;
  3. Prolonged QTc interval, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias;
  4. Active autoimmune diseases and inflammatory diseases;
  5. Diagnosis of another primary malignancy within 5 years prior to the first dose;
  6. Unstable thrombotic events requiring therapeutic intervention within 6 months prior to the first dose;
  7. Hypertension inadequately controlled by antihypertensive medications;
  8. Poorly controlled blood glucose (diabetes);
  9. History of interstitial lung disease (ILD) requiring corticosteroid therapy, or current ILD, or radiation pneumonitis of Grade ≥2;
  10. Severely impaired respiratory function;
  11. Active central nervous system (CNS) metastases;
  12. History of, or concurrent, central nervous system disorders;
  13. History of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or hypersensitivity to any excipient component of BL-M08D1;
  14. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
  15. Positive for human immunodeficiency virus (HIV) antibodies, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  16. Active infection requiring systemic therapy within 4 weeks prior to the first dose of study drug;
  17. Pleural, peritoneal, or pericardial effusion requiring drainage and/or associated with symptoms within 4 weeks prior to the first dose of study drug;
  18. Imaging findings indicating that the tumor has invaded or encased major blood vessels (e.g., abdominal or thoracic vessels), the pericardium, or the heart;
  19. Use of another investigational drug within 4 weeks or 5 half-lives prior to the first dose;
  20. Pregnant or breastfeeding women;
  21. Other conditions that, in the opinion of the investigator, make the patient unsuitable for participation in this clinical trial.

引自 ClinicalTrials.gov, NCT07818486, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07818486,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07818486